AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]
Go back to AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]| AbbVie (NYSE: ABBV) | Delayed: 264.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.48 | 52 Week High | $68.12 | |||
| Open | $264.48 | 52 Week Low | $50.71 | |||
| Day High | $264.48 | P/E | 57.37 | |||
| Day Low | $264.48 | EPS | $4.61 | |||
| Volume | 2,228 | |||||
